Skip to content

Dr Philip Kelly

Consultant Endocrinologist, Acute and General Physician

Year Qualified
Endocrinology, Acute and General Internal Medicine

Special Interests

  • Hypertension
  • Inpatient diabetes
  • Parathyroid
  • Pituitary, adrenal and thyroid disease
  • Salt and Water homeostasis
  • Sarcoidosis
  • Transfusion practice
  • Type 1 diabetes
  • Type 2 diabetes and complications
  • Venous thromboembolism


Dr Kelly is a Consultant Endocrinologist, Diabetologist, General and Acute Physician. He joined King’s in 2013 and was the Clinical Director and Lead for Acute Medicine at King’s College Hospital from 2014 – 2017. His current clinical work is in Acute and General Medicine, providing emergency and early care to all patients presenting to King’s under the Acute and General Medical Take. He has clinical expertise in managing and stabilising the acutely unwell, collaborating with Emergency Medicine, Critical Care, Diagnostic Imaging, Microbiology and Virology and other clinical specialities at King’s and across Lambeth and Southwark.

He has particular interests in:

  • endocrinology and diabetes
  • transfusion medicine and patient blood management, supporting restrictive blood transfusion and improving the diagnosis and management of anaemia
  • the diagnosis and management of infections of the lungs, brain and renal tract
  • the diagnosis and management of suspected and proven venous thromboembolism
  • the early and appropriate diagnosis and therapy of HIV.


He runs a hypertension outpatient clinic and provides specialist services as an Endocrinologist within the Sarcoidosis multi-disciplinary team.

His specialist clinical training – at St Bartholomew’s and The Royal London Hospitals – was in Endocrinology, Diabetes and General Internal Medicine. He undertook research for his MD thesis investigating the role of IGF-I on COX-2 expression and function in the colon of patients with and without acromegaly. He also undertook clinical research into the somatostatin analogue Lanreotide Autogel to control acromegaly, and described appropriate surveillance for colorectal neoplasia in acromegaly.

Related services